Hengrui PD-1 monoclonal antibody has once again submitted an application for listing in the USA. Will it replicate the approval path of Keytruda monoclonal antibody? | Speed Reading Announcement
①Today, jiangsu hengrui pharmaceuticals announced that it will resubmit the application for approval of Carirelizumab in the USA, after previously receiving a Complete Response Letter (CRL) from the US FDA, causing a delay; ②Junshi Bio's PD-1 variety also experienced delays in the USA but eventually succeeded in getting approved, industry insiders suggest that hengrui may replicate this process; ③If successfully approved in the USA, it would be of great significance to hengrui pharmaceuticals' global strategy.
Controlling shareholder's high quality pledge rate questioned, Tonghua Dongbao: revenue will gradually recover in the second half of the year | Earnings conference direct hit
①The high pledge rate of tonghua dongbao pharmaceutical's controlling shareholder's shares has been questioned, company's chairman Li Jiahong stated that it was due to the long investment cycle of Dongbao Group's projects; ② In terms of performance, Li Jiahong predicts that the company's revenue will gradually recover in the second half of the year; ③ The company also introduced the sales situation of new products.
Bullish on A-shares? Foreign capital bypasses Hong Kong stock ETFs, with institutions suggesting that incremental capital for Chinese stocks may reach 40 billion US dollars.
Institutions predict that Chinese stock potential incremental funds may reach 40 billion US dollars. Which directions will be the focus of increasing positions?
What happened during the National Day holiday at home and abroad? Here is a summary of important financial news.
①The Shanghai Stock Exchange: Will extend the acceptance of designated trading order instructions starting from October 8; Goldman Sachs has raised the Chinese stock market to "overweight", expecting a further increase of 15-20%; ②The Hong Kong stock market is booming, with a high growth in the number of brokerage account openings and margin trading data in Hong Kong in the past week; Many places have introduced optimization policies for real estate, and the market has responded positively.
Hong Kong stocks become the "hottest" stock market in the world! The Hang Seng Index has risen nearly 40% so far this year, with brokerage stocks surging sixfold in five days. How will the future market evolve?
It is noteworthy that brokerage stocks, as the vanguards of the bull market, play the role of "front-runners" in this current uptrend. Moreover, Chinese-affiliated brokerage stocks in the Hong Kong market have shown astonishing increases, indicated by the gains over the past five trading days.
Express News | Contract research organizations surged violently in the final trading session of Hong Kong stocks, with Tigermed soaring nearly 28%, Pharmaron rising over 22%, Joinn Laboratories up more than 17%, Wuxi Apptec up over 16%, and Wuxi Bio up over 14%.